Cognition Therapeutics Announces Participation in Upcoming September Conferences
August 30, 2023 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
November 28, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing...
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
June 23, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE...
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
January 10, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
November 30, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...